Drugs / R-TM123
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05949125 | Jan 2024 → May 2027 expected | acute myeloid leukemia | AvenCell Europe GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R-TM123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05949125 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant antibody derivative (R-TM123)” NCT05949125 ↗ |
| Route | Intravenous | “Intravenous infusion over 20 days” NCT05949125 ↗ |